日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Maplirpacept: a CD47 decoy receptor with minimal red blood cell binding and robust anti-tumor efficacy.

Maplirpacept:一种 CD47 诱饵受体,与红细胞结合极少,具有强大的抗肿瘤功效

Krishnamoorthy Mithunah, Seelige Ruth, Brown Christopher R, Chau Nancy, Nielsen Viller Natasja, Johnson Lisa D S, Linderoth Emma, Wang Jean C Y, Dillon Christopher P, Abayasiriwardana Keith, Lees Clare, Wong Mark, Kaneda Megan M, Uger Robert A, Lin Gloria H Y

Targeting CD47-SIRPa axis shows potent preclinical anti-tumor activity as monotherapy and synergizes with PARP inhibition

靶向 CD47-SIRPa 轴作为单药疗法显示出强大的临床前抗肿瘤活性,并且与 PARP 抑制剂具有协同作用。

Al-Sudani, Hussein; Ni, Ying; Jones, Philip; Karakilic, Huseyin; Cui, Lei; Johnson, Lisa D S; Rose, Peter G; Olawaiye, Alexander; Edwards, Robert P; Uger, Robert A; Lin, Gloria H Y; Mahdi, Haider

The pivotal role of cytotoxic NK cells in mediating the therapeutic effect of anti-CD47 therapy in mycosis fungoides

细胞毒性 NK 细胞在介导抗 CD47 疗法治疗蕈样肉芽肿中的关键作用

Oleg Kruglov, Lisa D S Johnson, Angela Minic, Kimberly Jordan, Robert A Uger, Mark Wong, Eric L Sievers, Yaping Shou, Oleg E Akilov

SIRPαFc treatment targets human acute myeloid leukemia stem cells

SIRPαFc疗法靶向人类急性髓系白血病干细胞

Galkin, Oleksandr; McLeod, Jessica; Kennedy, James A; Jin, Liqing; Mbong, Nathan; Wong, Mark; Uger, Robert A; Minden, Mark D; Danska, Jayne S; Wang, Jean C Y

Targeting pediatric leukemia-propagating cells with anti-CD200 antibody therapy

针对儿童白血病增殖细胞进行抗 CD200 抗体疗法

Paraskevi Diamanti, Charlotte V Cox, Benjamin C Ede, Robert A Uger, John P Moppett, Allison Blair

Use of an anti-CD200-blocking antibody improves immune responses to AML in vitro and in vivo

使用抗CD200阻断抗体可改善体外和体内针对急性髓系白血病(AML)的免疫反应。

Rastogi, Namrata; Baker, Sarah; Man, Stephen; Uger, Robert A; Wong, Mark; Coles, Steven J; Hodges, Marie; Gilkes, Amanda F; Knapper, Steven; Darley, Richard L; Tonks, Alex

Clinical Response to Anti-CD47 Immunotherapy Is Associated with Rapid Reduction of Exhausted Bystander CD4+ BTLA+ T Cells in Tumor Microenvironment of Mycosis Fungoides

抗 CD47 免疫疗法的临床反应与蕈样肉芽肿肿瘤微环境中耗竭的旁观者 CD4+ BTLA+ T 细胞的快速减少有关

Tony T Jiang, Oleg Kruglov, Gloria H Y Lin, Angela Minic, Kimberly Jordan, Robert A Uger, Mark Wong, Yaping Shou, Oleg E Akilov

Targeting CD47 in Sézary syndrome with SIRPαFc.

利用 SIRPαFc 靶向治疗 Sézary 综合征中的 CD47

Johnson Lisa D S, Banerjee Swati, Kruglov Oleg, Viller Natasja Nielsen, Horwitz Steven M, Lesokhin Alexander, Zain Jasmine, Querfeld Christiane, Chen Robert, Okada Craig, Sawas Ahmed, O'Connor Owen A, Sievers Eric L, Shou Yaping, Uger Robert A, Wong Mark, Akilov Oleg E

Development and Characterization of a Camelid Single Domain Antibody-Urease Conjugate That Targets Vascular Endothelial Growth Factor Receptor 2

开发和表征靶向血管内皮生长因子受体2的骆驼单域抗体-脲酶偶联物

Baomin Tian ,Wah Yau Wong ,Marni D Uger ,Pawel Wisniewski ,Heman Chao

TTI-621 (SIRPαFc), a CD47-blocking cancer immunotherapeutic, triggers phagocytosis of lymphoma cells by multiple polarized macrophage subsets

TTI-621 (SIRPαFc) 是一种阻断 CD47 的癌症免疫治疗药物,可触发多个极化巨噬细胞亚群吞噬淋巴瘤细胞

Gloria H Y Lin, Vien Chai, Vivian Lee, Karen Dodge, Tran Truong, Mark Wong, Lisa D Johnson, Emma Linderoth, Xinli Pang, Jeff Winston, Penka S Petrova, Robert A Uger, Natasja N Viller